Navigation Links
Burrill & Company CEO and Genzyme Executive Join BVGH Board of Directors
Date:10/11/2010

SAN FRANCISCO, Oct. 11 /PRNewswire-USNewswire/ -- BIO Ventures for Global Health (BVGH) announced today that G. Steven Burrill, Founder and Chief Executive Officer, Burrill & Company, and James A. Geraghty, Senior Vice President, Genzyme Corporation, have joined the organization's Board of Directors.  The addition of these two new board members rounds out the BVGH Board with a depth of expertise and experience in emerging markets and public-private partnerships.

"Both Steve Burrill and Jim Geraghty are long-standing colleagues in the biotech industry, deeply involved and widely respected," says Carl Feldbaum, Chair of BVGH's Board of Directors. "Their commitment and enthusiasm for biotechnology's increasing role in global health is beyond question. Our Board of Directors, staff, and donors are proud to have them now fully engaged in addressing the neglected diseases of the developing world."

Burrill founded Burrill & Company as a logical extension of his 40+ year involvement in the growth and prosperity of the biotechnology industry. Over the course of his career, Burrill has been an active advisor and catalyst to some of the industry's most well-known companies and transactions. Notably—prior to founding Burrill & Company in 1994—he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide.

In addition to his membership on BVGH's Board, Burrill currently serves as Chairman of the Boards of Pharmasset, Abunda Corporation, Foundation for the National Medals of Science and Technology, Vilas County Economic Development Corporation, and the World Council of Ethics.  He also serves as Chair of the San Francisco Mayor's Biotech Advisory Committee.  He is a member of the Boards of Directors of Catalyst Biosciences, DepoMed, NewBridge, Proventys, Targacept, and XDx. He serves as a member of the Board of various not-for-profit organizations including Bay Area Science Infrastructure Consortium (BASIC), The Kellogg Center for Biotechnology, the MIT Center for Biomedical Innovation, the National Health Museum, BioAg Gateway - City of Madison, University of Wisconsin College of Agriculture & Life Sciences, and the Scientific American Board of Advisors.

Geraghty is Senior Vice President of Genzyme Corporation and has played a leading role at the biotechnology company for over a decade.  He was President of Genzyme Europe from 1998-2002 and General Manager of Genzyme's cardiovascular business from 2003-2007.  He oversees Genzyme's strategic initiatives in emerging markets and has led many of the Company's largest transactions.  

Geraghty also oversees Genzyme's Humanitarian Assistance for Neglected Diseases program, under which Genzyme helps develop innovative therapeutic programs on a non-commercial basis. He has structured Genzyme's partnerships with Medicines for Malaria Venture, Brazil's Oswaldo Cruz Institute, and India's International Center for Genetic Engineering and Biotechnology. He served as Co-Chair of the Executive Committee for BIO 2007 and was a Steering Committee member of BVGH'S 2010 Partnering for Global Health Forum.  In addition to his membership on BVGH's Board, he serves as a Director of GTC Biotherapeutics (formerly Genzyme Transgenics Corporation), where he was Chairman and President and CEO, and of Bluebird Bio.

"Adding Steve Burrill and Jim Geraghty to our Board of Directors brings additional industrial and investor expertise to BVGH," says Melinda Moree, Chief Executive Officer of BVGH. "At a time when there is considerable activity in global health, it is critical that work aimed at incentivizing companies to work on new drugs, vaccines, and diagnostics for people in poor countries be grounded in the realities of companies and the investment community."

About BIO Ventures for Global Health

BIO Ventures for Global Health is a non-profit organization whose mission is to save lives by accelerating the development of novel biotechnology-based drugs, vaccines, and diagnostics to address the unmet medical needs of the developing world. The organization spurs biotech industry involvement in global health product development by increasing biotech and global health partnerships, designing and advocating for compelling market-based incentives, and synthesizing and disseminating critical information and quantitative analysis. For more information, please visit www.bvgh.org.


'/>"/>
SOURCE BIO Ventures for Global Health
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shawn Cross Joins Burrill Merchant Banking
2. Burrill & Company Invests in Taiwan Liposome Company
3. Joao Paulo Baptista Joins Burrill & Company
4. CEO of Burrill & Company to Speak at BioConference Live Slated for November 17th and 18th
5. Burrill & Company and WR Hambrecht + Co to Collaborate on OpenIPO(R) Transactions
6. Shawn Cross Appointed CEO of Burrill Merchant Banking Group
7. Burrill & Company Responds to Recent Press Coverage About Biopark Investment at Elk Run
8. CardioWest™ Artificial Heart Approved For Highest Reimbursement in CMS History : Plus Up To $53,000 New Technology Add-on Payments
9. 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis
10. Bruker Introduces HyperQuant™, a Unique Bench-Top NMR Reader to Quantify Hyperpolarization
11. Biotechnology & Drug Discovery Markets Push Up Demand for Lab Automation Products, According to a New Report by Global Industry Analysts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):